Biotech Blog

Moira Gunn’s Tech Nation interview of Jeremy Abbate and I on the Scientific American worldView project is now available at IT Conversations. For more details, you can also see our video interview and the worldView website.

At a recent event on the comparative advantages of small molecule vs. biologic drugs, several themes emerged which led me to re-examine the question of whether the practice of medicine is capable of keeping pace with medical innovation.
As mentioned in a previous post, the majority of patients receiving the personalized medicine drug Herceptin had not [...]

With two life science IPOs earlier this month, and seemingly fewer stories of biotechnology firm liquidations, it seems that the tides are turning — ever so slightly — in the favor of biotechnology.

Biotechnology Industry Organization CEO Jim Greenwood appeared on CNBC’s SquawkBox defending the case for data exclusivity protection for novel biologic drugs. The video appears below. Interestingly, he used the Aspirin vs. Epogen comparison from my book, Building Biotechnology, when he was explaining the difference between small molecule and biologic drugs to members of congress.

My most recent editorial in the Journal of Commercial Biotechnology, “The impact of the global financial crisis on biotechnology development,” examines the response of governments around the world to their investments in biotechnology and healthcare innovation. It is a theme that I also raised in the Scientific American WorldVIEW. The bottom line is: despite economic [...]

Here is a recent keynote I gave for the Delaware Valley Innovation Network. The group is working on coordinating the activities of community colleges — and other parties –  between the adjacent Delaware, Philadelphia, and New Jersey regions. My objective was to use case studies to show that drawing circles around regions to count combined [...]

After months of preparation, the Scientific American worldVIEW project has launched.
I had the pleasure of serving as lead editorial consultant of this project, and my mission was to cut through the marketing messages and develop a coherent measure of biotechnology innovation on a country-by-country basis. You can hear me talk about the project and some [...]

The Scientific American WorldView project, where I’ve been serving as lead editorial consultant, is ramping up for its May 20th launch at BIO 2009. One of the objectives for the project was to put marketing-speak aside and objectively measure biotechnology innovation progress around the world. Going beyond gross regional measures, we compare individual countries to [...]